M&As this week: Shenzhen Neptunus Bioengineering, Korea Value Asset Management, Catalent


Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan, China.

The company expects the acquisition to cost them up to $29.11m.

Korea Value Asset Management has acquired a 5% stake in biotech company ATGen.

"Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities."

The 5% stake represents 0.56m shares of the target company.

Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities.

Pursuant to the acquisition, Accucaps’ employees will join Calatent’s global network of softgel technologies and its blistering, bottling and packaging facilities will be included into Catalent’s softgel development and manufacturing units.

The acquisition enables Catalent to increase its production by the addition of new products.